focus -WSS

focus

author：knowledge 2025-09-04 05:33:21 - browse：532

A stethoscope lays on banknotes next to a calculator, all on top of a insurance application form — coverage from STAT — Adobe

Major insurance companies like UnitedHealthcare and Humana have edged out private equity firms from investing in Medicare Advantage, according to a new report.

But investors have found pockets of profits by backing companies involved in enrolling seniors in MA plans and keeping track of them once they’re there. They’re investing in insurance brokerages, marketers, in-home assessment companies, and “insurtechs,” the report said, based on a new analysis of deals in the space since 2016.

Overall, private equity investors made only 4 investments in Medicare Advantage-related companies last year, compared with 12 in 2022, down from a peak of 19 in 2021, per the Private Equity Stakeholder Project, a group focused on holding private equity firms accountable for their impacts on people and the planet, according to its website.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Why more medical students aren't specializing in primary care

focus

WSS

Radiation, mainstay of cancer treatment, begins a fade

Teach medical students about patients with intellectual disabilities

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Spinal cord stimulation reduces pain in amputees, study finds

Departing Stanford president retracts two papers

What AAP's gender

knowledge

focus

focus

In age of alternative facts, a scholarly course on calling out crap

Leukemia patients are helped by Syndax's new type of therapy

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What AAP's gender

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves world's first CRISPR

Supreme Court strikes down use of affirmative action

Roche to buy Carmot Therapeutics, developer of obesity drugs

Duchenne breakthrough therapy leaves behind pioneering families

Apellis safety probe of eye disease drug centers on injection needle

hotspot

STAT letters to the editor on burnt

Apellis safety probe of eye disease drug centers on injection needle

Australia’s approach to dialysis celebrates life

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Why sickle cell disease is getting the first CRISPR treatment

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

explore

focus

focus

Wikipedia